{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:51:33Z","timestamp":1792039893118,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T00:00:00Z","timestamp":1442361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/nrmicro3523","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T05:51:09Z","timestamp":1442382669000},"page":"651-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cooperative development of antimicrobials: looking back to look ahead"],"prefix":"10.1038","volume":"13","author":[{"given":"Carl","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,16]]},"reference":[{"key":"BFnrmicro3523_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMp1408040","volume":"371","author":"C Nathan","year":"2014","unstructured":"Nathan, C. & Cars, O. Antibiotic resistance\u2014problems, progress, and prospects. New Engl. J. Med. 371, 1761\u20131763 (2014).","journal-title":"New Engl. J. Med."},{"key":"BFnrmicro3523_CR2","volume-title":"Review on Antimicrobial Resistance","author":"JC O'Neill","year":"2014","unstructured":"O'Neill, J. C. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance \n                    [online]\n                    \n                  , (2014)."},{"key":"BFnrmicro3523_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/431899a","volume":"431","author":"C Nathan","year":"2004","unstructured":"Nathan, C. Antibiotics at the crossroads. Nature 431, 899\u2013902 (2004).","journal-title":"Nature"},{"key":"BFnrmicro3523_CR4","volume-title":"The Mould in Dr Florey's Coat: the Remarkable True Story of Penicillin","author":"E Lax","year":"2004","unstructured":"Lax, E. The Mould in Dr Florey's Coat: the Remarkable True Story of Penicillin (Little, Brown & Co., 2004)."},{"key":"BFnrmicro3523_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/149328b0","volume":"149","author":"EP Abraham","year":"1942","unstructured":"Abraham, E. P. & Chain, A. Purification of penicillin. Nature 149, 328\u2013328 (1942).","journal-title":"Nature"},{"key":"BFnrmicro3523_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0140-6736(00)72122-2","volume":"238","author":"EP Abraham","year":"1941","unstructured":"Abraham, E. P. et al. Further observations on penicillin. Lancet 238, 177\u2013189 (1941).","journal-title":"Lancet"},{"key":"BFnrmicro3523_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(01)08728-1","volume":"236","author":"E Chain","year":"1940","unstructured":"Chain, E. et al. Penicillin as a chemotherapeutic agent. Lancet 236, 226\u2013228 (1940).","journal-title":"Lancet"},{"key":"BFnrmicro3523_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1017\/S0007087400026789","volume":"16","author":"JP Swann","year":"1983","unstructured":"Swann, J. P. The search for synthetic penicillin during World War II. Br. J. Hist. Sci. 16, 154\u2013190 (1983).","journal-title":"Br. J. Hist. Sci."},{"key":"BFnrmicro3523_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1023\/A:1015760920428","volume":"40","author":"N Rasmussen","year":"2002","unstructured":"Rasmussen, N. Of \u201csmall men\u201d, big science and bigger business: the Second World War and biomedical research in the United States. Minerva 40, 115\u2013146 (2002).","journal-title":"Minerva"},{"key":"BFnrmicro3523_CR10","volume-title":"Penicillin Man: Alexander Fleming and the Antibiotic Revolution","author":"K Brown","year":"2004","unstructured":"Brown, K. Penicillin Man: Alexander Fleming and the Antibiotic Revolution (Sutton Publishing, 2004)."},{"key":"BFnrmicro3523_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/00000658-194608000-00017","volume":"124","author":"JS Lockwood","year":"1946","unstructured":"Lockwood, J. S. War-time activities of the National Research Council and the Committee on Medical Research: with particular reference to team-work on studies of wounds and burns. Ann. Surg. 124, 314\u2013327 (1946).","journal-title":"Ann. Surg."},{"key":"BFnrmicro3523_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jama.1943.02840350001001","volume":"122","author":"CS Keefer","year":"1943","unstructured":"Keefer, C. S. et al. Penicillin in the treatment of infections. A report of 500 cases. JAMA 122, 1217\u20131224 (1943).","journal-title":"JAMA"},{"key":"BFnrmicro3523_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.1943.02840210027012","volume":"122","author":"AN Richards","year":"1943","unstructured":"Richards, A. N. Penicillin. Statement released by the Committee on Medical Research. JAMA 122, 235\u2013236 (1943).","journal-title":"JAMA"},{"key":"BFnrmicro3523_CR14","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1021\/ja01562a063","volume":"79","author":"JC Sheehan","year":"1957","unstructured":"Sheehan, J. C. & Henery-Logan, K. R. The total synthesis of penicillin V. J. Am. Chem. Soc. 79, 1262\u20131263 (1957).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrmicro3523_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1126\/science.92.2382.176","volume":"192","author":"LT Coggeshall","year":"1940","unstructured":"Coggeshall, L. T. et al. Research work on chemotherapy. Science 192, 176\u2013178 (1940).","journal-title":"Science"},{"key":"BFnrmicro3523_CR16","volume-title":"The Malaria Project: The U.S. Government's Secret Mission to Find a Miracle Cure","author":"KM Masterson","year":"2014","unstructured":"Masterson, K. M. The Malaria Project: The U.S. Government's Secret Mission to Find a Miracle Cure (New American Library, 2014)."},{"key":"BFnrmicro3523_CR17","volume-title":"War and Disease","author":"LB Slater","year":"2014","unstructured":"Slater, L. B. War and Disease (Rutgers Univ. Press, 2014)."},{"key":"BFnrmicro3523_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4269\/ajtmh.1963.12.121","volume":"12","author":"GR Coatney","year":"1963","unstructured":"Coatney, G. R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 12, 121\u2013128 (1963).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFnrmicro3523_CR19","unstructured":"World Health Organization. Making a difference: 30 years of research and capacity building in tropical diseases. WHO \n                    [online]\n                    \n                  , (2007)."},{"key":"BFnrmicro3523_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.pt.2006.05.011","volume":"22","author":"I Bathurst","year":"2006","unstructured":"Bathurst, I. & Hentschel, C. Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol. 22, 301\u2013307 (2006).","journal-title":"Trends Parasitol."},{"key":"BFnrmicro3523_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bcp.12401","volume":"79","author":"S O'Brien","year":"2015","unstructured":"O'Brien, S. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry. Br. J. Clin. Pharmacol. 79, 168\u2013172 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrmicro3523_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrmicro3245","volume":"12","author":"JH Rex","year":"2014","unstructured":"Rex, J. H. ND4BB: addressing the antimicrobial resistance crisis. Nat. Rev. Microbiol. 12, 231\u2013232 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnrmicro3523_CR23","doi-asserted-by":"publisher","first-page":"228ed7","DOI":"10.1126\/scitranslmed.3008605","volume":"6","author":"RA Stavenger","year":"2014","unstructured":"Stavenger, R. A. & Winterhalter, M. TRANSLOCATION project: how to get good drugs into bad bugs. Sci. Transl. Med. 6, 228ed7 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnrmicro3523_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1228980","volume":"339","author":"S Chakraborty","year":"2013","unstructured":"Chakraborty, S. et al. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88\u201391 (2013).","journal-title":"Science"},{"key":"BFnrmicro3523_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrmicro3200","volume":"12","author":"V Dartois","year":"2014","unstructured":"Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159\u2013167 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnrmicro3523_CR26","doi-asserted-by":"publisher","first-page":"19095","DOI":"10.1073\/pnas.1315860110","volume":"110","author":"JH Kim","year":"2013","unstructured":"Kim, J. H. et al. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc. Natl Acad. Sci. USA 110, 19095\u201319100 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrmicro3523_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1126\/science.1193225","volume":"329","author":"M Rottmann","year":"2010","unstructured":"Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175\u20131180 (2010).","journal-title":"Science"},{"key":"BFnrmicro3523_CR28","doi-asserted-by":"publisher","first-page":"c2115","DOI":"10.1136\/bmj.c2115","volume":"340","author":"CM Morel","year":"2010","unstructured":"Morel, C. M. & Mossialos, E. Stoking the antibiotic pipeline. BMJ 340, c2115 (2010).","journal-title":"BMJ"},{"key":"BFnrmicro3523_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nm0307-304","volume":"13","author":"C Nathan","year":"2007","unstructured":"Nathan, C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304\u2013308 (2007).","journal-title":"Nat. Med."},{"key":"BFnrmicro3523_CR30","doi-asserted-by":"publisher","first-page":"140sr2","DOI":"10.1126\/scitranslmed.3003081","volume":"4","author":"C Nathan","year":"2012","unstructured":"Nathan, C. Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4, 140sr2 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrmicro3523_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29\u201340 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrmicro3523_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","volume":"6","author":"SJ Projan","year":"2003","unstructured":"Projan, S. J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427\u2013430 (2003).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnrmicro3523_CR33","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1073\/pnas.1503141112","volume":"112","author":"TP Van Boekel","year":"2015","unstructured":"Van Boekel, T. P. et al. Global trends in antimicrobial use in food animals. Proc. Natl Acad. Sci. USA 112, 5649\u20135654 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrmicro3523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro3523","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrmicro3523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:41:09Z","timestamp":1684471269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrmicro3523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,16]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFnrmicro3523"],"URL":"https:\/\/doi.org\/10.1038\/nrmicro3523","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,16]]},"assertion":[{"value":"16 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.N. is a participant in the Tuberculosis Drug Accelerator (TBDA) (funded by the Bill & Melinda Gates Foundation) and a member of the Board of Governors of the Tres Cantos Open Lab Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}